A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Fredrik Sundquist, Kleopatra Georgantzi, Kirsten Brunsvig Jarvis, Jesper Brok, Minna Koskenvuo, Jelena Rascon, Max van Noesel, Per Grybäck, Joachim Nilsson, Arthur Braat, Mikael Sundin, Sandra Wessman, Nikolas Herold, Lars Hjorth, Per Kogner, Dan Granberg, Mark Gaze, Jakob Stenman

Open source

DOI: 10.3389/fped.2022.836230
Published: 2022-03-10
Container: Frontiers in Pediatrics
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fped.2022.836230,
  title = {A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N},
  author = {Fredrik Sundquist and Kleopatra Georgantzi and Kirsten Brunsvig Jarvis and Jesper Brok and Minna Koskenvuo and Jelena Rascon and Max van Noesel and Per Grybäck and Joachim Nilsson and Arthur Braat and Mikael Sundin and Sandra Wessman and Nikolas Herold and Lars Hjorth and Per Kogner and Dan Granberg and Mark Gaze and Jakob Stenman},
  year = {2022},
  journal = {Frontiers in Pediatrics},
  doi = {10.3389/fped.2022.836230},
  url = {https://doi.org/10.3389/fped.2022.836230}
}

RIS

TY  - JOUR
TI  - A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
AU  - Fredrik Sundquist
AU  - Kleopatra Georgantzi
AU  - Kirsten Brunsvig Jarvis
AU  - Jesper Brok
AU  - Minna Koskenvuo
AU  - Jelena Rascon
AU  - Max van Noesel
AU  - Per Grybäck
AU  - Joachim Nilsson
AU  - Arthur Braat
AU  - Mikael Sundin
AU  - Sandra Wessman
AU  - Nikolas Herold
AU  - Lars Hjorth
AU  - Per Kogner
AU  - Dan Granberg
AU  - Mark Gaze
AU  - Jakob Stenman
PY  - 2022
JO  - Frontiers in Pediatrics
DO  - 10.3389/fped.2022.836230
UR  - https://doi.org/10.3389/fped.2022.836230
ER  -

APA

Sundquist, F., Georgantzi, K., Jarvis, K. B., Brok, J., Koskenvuo, M., Rascon, J., Noesel, M. V., Grybäck, P., Nilsson, J., Braat, A., Sundin, M., Wessman, S., Herold, N., Hjorth, L., Kogner, P., Granberg, D., Gaze, M., & Stenman, J. (2022). A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N. Frontiers in Pediatrics. https://doi.org/10.3389/fped.2022.836230

Source records

crossref · retrieved 2026-09-27T04:38:02.429Z